Literature DB >> 12113091

Molecular and pharmacological strategies to overcome multidrug resistance.

J A Shabbits1, R Krishna, L D Mayer.   

Abstract

Multidrug resistance is a major obstacle to the effective treatment of cancer. Despite vast improvements in our understanding of the mechanisms of drug resistance, relatively few significant advances have been made towards effectively circumventing it in a clinical setting. The ability to modulate multidrug resistance has been complicated by the fact that many human tumors simultaneously exhibit multiple resistance mechanisms. In order to effectively overcome multidrug resistance it will be necessary to design new strategies that combine multiple modulating agents and approaches. This review provides an overview of the major causes of multidrug resistance and summarizes many of the current approaches being taken to overcome it. We also describe how liposomal drug delivery systems can be utilized to aid in achieving these goals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12113091     DOI: 10.1586/14737140.1.4.585

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  6 in total

1.  Cyclostreptin derivatives specifically target cellular tubulin and further map the paclitaxel site.

Authors:  Enrique Calvo; Isabel Barasoain; Ruth Matesanz; Benet Pera; Emilio Camafeita; Oriol Pineda; Ernest Hamel; Christopher D Vanderwal; José Manuel Andreu; Juan A López; José Fernando Díaz
Journal:  Biochemistry       Date:  2011-12-30       Impact factor: 3.162

2.  Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Ping Xie; Xin Gu; Armando E Giuliano; Myles C Cabot
Journal:  Int J Oncol       Date:  2011-05-23       Impact factor: 5.650

3.  Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.

Authors:  Eugen Ruckhäberle; Thomas Karn; Lars Hanker; Regine Gätje; Dirk Metzler; Uwe Holtrich; Manfred Kaufmann; Achim Rody
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-17       Impact factor: 4.553

Review 4.  Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Authors:  Ameya R Kirtane; Stephen M Kalscheuer; Jayanth Panyam
Journal:  Adv Drug Deliv Rev       Date:  2013-09-10       Impact factor: 15.470

5.  The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.

Authors:  Pei-Rong Ding; Amit K Tiwari; Shinobu Ohnuma; Jeferson W K K Lee; Xin An; Chun-Ling Dai; Qi-Si Lu; Satyakam Singh; Dong-Hua Yang; Tanaji T Talele; Suresh V Ambudkar; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2011-04-28       Impact factor: 3.240

6.  High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design.

Authors:  Oskía Bueno; Juan Estévez Gallego; Solange Martins; Andrea E Prota; Federico Gago; Asier Gómez-SanJuan; María-José Camarasa; Isabel Barasoain; Michel O Steinmetz; J Fernando Díaz; María-Jesús Pérez-Pérez; Sandra Liekens; Eva-María Priego
Journal:  Sci Rep       Date:  2018-03-09       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.